1. Health technology

  2. •

    Pharmaceuticals: major
Roche Holding Ltd

Roche Holding Ltd

432.20
EUR
+17.80
(+4.30%)
297.51BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
55.17
55.9
56.57
59.36
62.48
66.56
71.81
68.21
73.88
82.27
75.65
78.29
79.59
- -
Basic EPS, GAAP
13.17
10.99
10.41
11.24
10.12
12.3
15.77
16.72
16.39
15.53
14.39
10.39
16.18
- -
Free Cash Flow per Basic Share
15.23
14.84
13.09
11.57
16.19
17.63
20.43
13.89
19.33
16.56
14.33
18.93
16.42
- -
Dividend per Share
7.5
7.91
8.17
8.26
8.37
8.49
8.7
9.01
9.14
9.31
9.5
9.6
9.71
- -
Book Value per Share
22.72
23.05
24.62
28.07
30.97
32.35
38.27
42.6
30.6
35.03
36.77
39.94
42.49
41.03
Tangible Book Value per Share
9.66
-3.7
-4.65
0.68
9.36
10.92
13.67
17.67
1.95
9.37
6.39
8.28
8.78
7.03
Basic Weighted Avg Shares
848
849
851
852
853
854
856
855
850
800
799
797
796
796
Sales/Revenue/Turnover
46,780
47,462
48,145
50,576
53,299
56,846
61,466
58,323
62,801
65,814
60,441
62,395
63,356
- -
Operating Margin (%)
35.01
29.69
28.71
27.82
24.4
25.98
28.55
31.79
28.91
26.55
25.47
21.5
29.16
- -
Depreciation Expense
2,381
2,623
3,640
3,941
3,887
3,586
4,292
4,558
4,443
3,844
3,464
3,423
3,386
- -
Net Income, GAAP
11,164
9,332
8,863
9,576
8,633
10,500
13,497
14,295
13,930
12,421
11,498
8,277
12,880
- -
Effective Tax Rate (%)
22.51
23.81
24.45
25.17
27.95
23.2
15.08
16.13
14.16
17.13
12.22
22.1
18.7
- -
Profit Margin (%)
23.86
19.66
18.41
18.93
16.2
18.47
21.96
24.51
22.18
18.87
19.02
13.27
20.33
- -
Working Capital
13,404
8,006
4,414
6,070
9,412
9,211
7,135
7,541
-2,789
6,577
8,622
13,013
10,728
6,590
LT Debt
16,423
19,347
17,100
16,992
15,839
16,077
13,547
11,096
17,101
22,282
26,092
32,097
28,674
25,222
Total Equity
21,241
21,558
23,300
26,402
29,007
30,366
35,867
39,773
28,345
32,015
33,263
36,161
37,880
36,716
Return on Invested Capital (%)
29.84
23.5
21.12
20.95
18.26
21.79
27.59
27.28
25.4
23.07
21.1
14.73
20.08
- -
Return on Capital (%)
29.52
23.01
20.28
21.27
18.59
22.09
26.96
26.23
22.89
19.89
18.78
12.39
18.18
- -
Return on Common Equity (%)
66.04
48
43.7
42.66
34.29
38.84
44.72
41.38
45.8
47.34
40.13
27.1
39.29
- -

Capital Structure

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
6,567
4,517
6,583
LT Borrowings
26,464
27,430
25,222
LT Finance Leases
- -
1,244
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
796
796
797
Market Capitalization
218,550
269,284
274,579

Working Capital

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
35,702
38,729
35,437
Cash, Cash Equivalents & STI
12,026
15,476
9,734
Accounts Receivable, Net
11,918
12,391
12,915
Inventories
7,597
7,479
8,094
Total Current Liabilities
27,580
28,001
28,847
Payables & Accruals
- -
- -
- -
ST Debt
6,567
4,517
6,583
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.85%
0.32%
4.75%
Free Cash Flow
4.55%
4.76%
-13.34%
Net Income, GAAP
6.11%
1.36%
55.61%
Sales/Revenue/Turnover
2.92%
1.82%
1.54%
Total Cash Common Dividend
1.08%
0.1%
1.06%

Quarterly Revenue

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
62,395
2025
- -
- -
- -
- -
63,356
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
10.39
2025
- -
- -
- -
- -
16.18
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
9.6
2025
- -
- -
- -
- -
9.71
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
Address
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business

Company News

Company News APIChatGPT

  • businesswire.com

    Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

  • businesswire.com

    Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)

  • globenewswire.com

    Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

  • seekingalpha.com

    Roche Holding AG (RHHBY) Q3 2026 Sales/Trading Call Transcript

  • zacks.com

    Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances

  • wsj.com

    Roche Posts Higher Sales on Growth Across Pharma, Diagnostics Units

  • reuters.com

    Roche third quarter sales slightly beat expectations with growth across divisions

  • globenewswire.com

    [Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]

  • globenewswire.com

    [Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starke Dynamik im dritten Quartal mit Umsatzwachstum von +7% zu konstanten Wechselkursen (CER) und +8% in CHF fort; Konzernverkäufe steigen in den ersten neun Monaten 2026 um +6% (CER) […]

  • reuters.com

    Roche says experimental MS pill cuts relapses by 55% in late-stage trials

  • wsj.com

    Roche Partners With China's Hansoh in Deal That Could Top $15 Billion

  • reuters.com

    Roche to unveil lung, breast cancer data at ESMO 2026

  • zacks.com

    Roche Gets FDA Approval for Enspryng in Thyroid Eye Disease

  • zacks.com

    4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month

  • zacks.com

    Roche Expands Obesity Pipeline With Rona's RNAi Candidate

  • reuters.com

    Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics

  • zacks.com

    Roche Reports Positive Phase III Data on Eye Drug, FDA Accepts BLA

  • zacks.com

    Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines

  • businesswire.com

    Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

  • prnewswire.com

    Gen Announces Appointment of Talbott Roche to Board of Directors